Dear Internal Market, Industry, Entrepreneurship and SMEs (DG GROW),

On behalf of Corporate Europe Observatory (CEO), I would like to - under the right of access to documents in the EU treaties as developed in Regulation 1049/2001 - request access to the following documents:

- all reports (and other notes) from meetings between DG GROW and representatives of the pharmaceutical industry (companies as well as organisations such as EFPIA) from December 1st 2019 onwards. This should include the following companies: Bayer AG, Novartis International AG, Merck, GlaxoSmithKline, Amgen Inc, F. Hoffmann-La Roche Ltd, Johnson & Johnson, SANOFI, Pfizer Inc., AstraZeneca, Eli Lilly and Company, and MSD (Europe) Inc. (Merck Sharp & Dohme).

- all correspondence (including emails) between the DG GROW and representatives of the pharmaceutical industry (companies as well as organisations such as EFPIA) from December 1st 2019 onwards.

- a list of all the above-mentioned documents (including dates, names of participants/senders/recipients and their affiliation, subject of meeting/correspondence)

Yours faithfully,
Olivier Hoedeman

on behalf of Corporate Europe Observatory (CEO)
Corporate Europe Observatory (CEO)
Rue d'Edimbourg 26,
1050 Brussels, Belgium

http://www.corporateeurope.org
Tel. +32 (0)2 893 0930
Mobile: +32 474 486545
EU Transparency Register ID Number: 5353162366-85

Internal Market, Industry, Entrepreneurship and SMEs

1 Attachment

Dear Mr Hoedeman,
 
We thank you for your requests for access to documents received on
12/02/2020.
Please note that we received an identical request from you on 16/01/2020
registered under GestDem 2020/0311. For this reason, please note that you
will receive only one reply letter under Gestdem 2020/0311.
 
Thank you very much for your understanding.
 
Kind regards,
 
DG GROW – Access to documents team
European Commission
Directorate-General for Internal Market, Industry, Entrepreneurship and
SMEs
DG GROW/01 – Coordination and Planning
 
 

show quoted sections

Dear Internal Market, Industry, Entrepreneurship and SMEs,

thanks very much, that's perfectly fine.

Yours faithfully,

Olivier Hoedeman